Current understanding and challenges in bioprocessing of stem cell-based therapies for regenerative medicine

Abstract

Background: A novel manufacturing industry is emerging to translate unique cellular therapy bioprocesses to robust, scaled manufacturing production for successful clinical translation.

Source of data: This review summarizes key translational issues, and current and future perspectives to improve translation of cell-based therapy bioprocessing, based on literature search and author research.

Areas of agreement: It is widely recognized that cell-based therapies could revolutionize health care for a range of diseases, and that there are gaps in the overarching framework and technologies to generate clinical success.

Areas of controversy: There is limited understanding of how to fulfil requirements as regulatory and manufacturing guidelines are incomplete and few have achieved commercialization.

Growing points: Recent developments are encouraging adoption of automation and quality engineering approaches for bioprocessing of cell-based therapies.

Areas timely for developing research: Include technology development to improve the cost and purity of manufacture and final product quality.